Compare Amphastar Pharmaceuticals Inc (AMPH) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Lufax Holding Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Lufax Holding Ltd trades at $1.56 (market cap $2.41B). The key difference: Lufax Holding Ltd is far larger — about 2.8× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Lufax Holding Ltd nearer its low. Which is the better fit depends on your goals.
| AMPH | LU | |
|---|---|---|
Market Cap | $863.95M | $2.41B |
Sector | Health | Technology |
52-Week High | $30.81 | $4.40 |
52-Week Low | $16.87 | $1.23 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
LU trades at $1.50, up 0.67% on the day, with a neutral technical signal and bearish moving averages. The stock shows deep value on price-to-sales (0.42) and price-to-book (0.12) ratios but faces profitability challenges with a -9.08% net margin and negative ROE. Recent earnings misses and a securities class action lawsuit filed in May 2026 create headwinds, though analyst consensus remains 69% buy-rated.
The outlook is cautious due to litigation overhangs and persistent losses, but low valuations may attract value investors if operational improvements materialize. Key risks include legal liabilities and execution on turning profitability; upside depends on management's ability to stabilize earnings amid competitive pressures in Chinese financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
